6 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
9 Aug 22
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
12:00am
season in the second half of 2022, the Company expects to initiate a Phase 2 prophylaxis healthy volunteer trial evaluating the safety and efficacy
8-K
EX-99.2
VIR
Vir Biotechnology Inc
28 Jan 21
Other Events
4:05pm
alone or administered with VIR-7831 or etesevimab will receive regulatory approvals or additional authorizations, that patients will volunteer
S-1
EX-10.21
VIR
Vir Biotechnology Inc
3 Sep 19
IPO registration
4:40pm
and/or to gain early evidence of the effectiveness of a pharmaceutical product for a particular indication or indications in normal volunteer subjects
S-1
EX-10.35
VIR
Vir Biotechnology Inc
3 Sep 19
IPO registration
4:40pm
in volunteer subjects or patients that would satisfy the requirements of 21 CFR 312.21(a), or its foreign equivalent and may evaluate the Licensed
DRS/A
EX-10.35
yk8pmc hwh
7 Aug 19
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next